Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Summary

Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal antibody therapy in treating patients who have metastatic prostate cancer that has not responded to previous hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab may stop the growth of cancer cells by stopping blood flow to the tumor. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.

Timeline

Start

2001-06

Primary completion

2007-02

Completion

—

Drugs

Indications